New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
NCT ID: NCT06647095
Last Updated: 2024-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
172 participants
OBSERVATIONAL
2021-09-01
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Can a method find participants with higher liver fat than healthy participants?
2. Can a method find participants in whom higher liver fat was a cause of liver inflammation or stiffness?
Participants will:
* fast overnight
* have a routine blood draw
* easily exhale a few times into a special device or a plastic bag and fill in a short dietary questionnaire (if participating in a breath test)
* optionally swallow capsules with an orange peel extract and fish oil before exhaling, which can help get better results from breath (capsules will be medically safe and approved)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
NCT04873258
Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women
NCT06682663
Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease
NCT01798719
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
NCT01936779
Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)
NCT02458586
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
First, this study aims to differentiate patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) from healthy controls (or simple steatosis) using three experimental methods.
Second, the investigators aim to stratify patients with MASLD according to the presence/grade of steatosis and fibrosis (any, significant F2-3, advanced F3, cirrhosis F4) using the same methods.
Experimental methods tested in this study include:
1. analyzing the fasting spectrum of serum bile acids using liquid chromatography-mass spectrometry
2. analyzing the disease-specific spectroscopy patterns given by vibrational and chiroptical spectroscopy of blood plasma
3. analyzing trace concentrations of volatile organic compounds (VOC) in exhaled human breath using the Selected ion flow tube mass spectrometry. This contains the so-called stress test to monitor breath VOC (d-Limonene and triethylamine) after their regulated ingestion in the form of capsules
These parameters may eventually be combined with anthropometric and laboratory parameters (such as age or BMI).
Clinical examinations, blood sampling, ultrasound examinations of the liver, and liver elastography will be performed as part of routine care.
The results of the blood parameters can be retrospectively evaluated.
Approximately 60-80 participants in total were anticipated for each method. For patients who participate in breath tests, adequate insurance must be guaranteed.
Statistical processing: individual parameters will be evaluated in an exploratory and a validation group or by the PLS-DA algorithm with repeated cross-validation. A difference of p \<0.05 will be considered a statistically significant change.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy controls
D-Limonene Gelcaps
Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
Fish Oil Concentrate, 1000 Mg Oral Capsule
Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
MASH
D-Limonene Gelcaps
Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
Fish Oil Concentrate, 1000 Mg Oral Capsule
Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
Steatosis
D-Limonene Gelcaps
Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
Fish Oil Concentrate, 1000 Mg Oral Capsule
Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-Limonene Gelcaps
Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups
Fish Oil Concentrate, 1000 Mg Oral Capsule
Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of secondary causes of fat accumulation in the liver and other liver disease: ruled out other etiologies of liver disease, such as viral hepatitis, drug-induced liver disease, autoimmune liver disease, biliary tract disease, and hereditary metabolic diseases
* Absence of liver disease
* For breath analysis: absence of liver steatosis (normal liver ultrasound image and CAP less than 248 dB/m)
* For plasma spectroscopy and bile acid analysis: Body Mass Index ≤ 25 and waist-hip ratio ≤ 0.95 plus normal liver ultrasound
* Absence of diabetes mellitus and metabolic syndrome
* Normal liver function tests, lipid spectrum, fasting glycemia
* Alcohol intake less than 20 g/ day (women) or 30 g/ day (men)
Exclusion Criteria
* Failure to sign the informed consent form
* Liver biopsy/clinic discrepancy
* For LMN a TMA "stress test": fish, see fruit and citrus fruit allergy
* Pregnancy
* For bile acid analysis: Treatment with BA or BA sequestrants
* For bile acid analysis: Portal hypertension (does not apply for MASH patients)
* For bile acid analysis: Cirrhosis (does not apply for MASH patients)
* For plasma spectroscopy: Cirrhosis
* Anamnesis of alcohol abuse (based on GGT, carbohydrate-deficient transferrin, urinary ethyl-glucuronide, and patient's history)
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General University Hospital, Prague
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbora Nováková, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbora Nováková, MD
Role: PRINCIPAL_INVESTIGATOR
General University Hospital, Prague
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Regional Hospital Liberec
Liberec, Czech Republic, Czechia
General University Hospital in Prague
Prague, Czech Republic, Czechia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Zizalova K, Novakova B, Vecka M, Petrtyl J, Lanska V, Pelinkova K, Smid V, Bruha R, Vitek L, Lenicek M. Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension. Liver Int. 2023 Apr;43(4):888-895. doi: 10.1111/liv.15481. Epub 2022 Nov 25.
WED-280 Spectroscopy of blood plasma has the potential to differentiate metabolic dysfunction-associated steatohepatitis from steatosis Nováková, Barbora et al. Journal of Hepatology, Volume 80, S539 - S540
Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018 Feb;67(2):534-548. doi: 10.1002/hep.29359. Epub 2017 Dec 23.
Spanel P, Smith D. Quantification of volatile metabolites in exhaled breath by selected ion flow tube mass spectrometry, SIFT-MS. Clin Mass Spectrom. 2020 Feb 13;16:18-24. doi: 10.1016/j.clinms.2020.02.001. eCollection 2020 Apr.
Sinha R, Lockman KA, Homer NZM, Bower E, Brinkman P, Knobel HH, Fallowfield JA, Jaap AJ, Hayes PC, Plevris JN. Volatomic analysis identifies compounds that can stratify non-alcoholic fatty liver disease. JHEP Rep. 2020 Jun 15;2(5):100137. doi: 10.1016/j.jhepr.2020.100137. eCollection 2020 Oct.
Ten-Doménech I, Rienda I, Pérez-Rojas J, et al. Progress and challenges of mid-infrared spectroscopy for liver characterization focusing on steatosis, fibrosis and cancer. Applied Spectroscopy Reviews. 2024;59(4):578-599
Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024 Mar 7;73(4):691-702. doi: 10.1136/gutjnl-2023-330595.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GUHPrague83/21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.